![Michael Grey](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Grey
Fondateur chez
MIRUM PHARMACEUTICALS, INC.
Fortune : 29 M $ au 31/05/2026
Profil
Michael G.
Grey was the founder of Reneo Pharmaceuticals, Inc., founded in 2014, where the title held was Executive Chairman from 2017 to 2024.
Mr. Grey is the founder of Mirum Pharmaceuticals, Inc., founded in 2018, holding the title of Chairman since 2020.
Current jobs include Chairman at Sorriso Pharmaceuticals, Inc. since 2017; Executive Chairman at Plexium, Inc. since 2021; Executive Chairman at Spruce Biosciences, Inc. since 2022; Vice Chairman at Biothera, Inc.; Executive Chairman at Theolytics Ltd. since 2023; Director at OnKure Therapeutics, Inc. since 2024; and Venture Partner at Pappas Capital LLC since 2010.
Former jobs include President & Chief Executive Officer at SGX Pharmaceuticals, Inc. from 2005 to 2008; President & Chief Executive Officer at Auspex Pharmaceuticals, Inc. in 2009; President & Chief Executive Officer at Lumena Pharmaceuticals, Inc. from 2011 to 2014; President, Chief Executive Officer & Director at Trega Biosciences, Inc. from 1998 to 2001; Non-Executive Chairman at IDM Pharma, Inc. from 1999 to 2009; Executive Chairman at Curzion Pharmaceuticals, Inc. from 2019 to 2020; Executive Chairman at Ziarco Group Ltd. from 2015 to 2017; Director at Amplyx Pharmaceuticals, Inc. from 2020 to 2021; Director at Achillion Pharmaceuticals, Inc. from 2001 to 2010; Lead Independent Director at Horizon Pharma, Inc. from 2013 to 2014; Independent Director at Mirati Therapeutics, Inc. from 2014 to 2021; Lead Independent Director at Horizon Therapeutics Ltd. (Ireland) from 2012 to 2023; Independent Non-Executive Director at BioMarin Pharmaceutical, Inc. from 2014 to 2021; Vice President-Corporate Development at Glaxo Holdings Plc and Glaxo, Inc. from 1974 to 1993; President at Biochem Therapeutic, Inc. from 1994 to 1998; and other director and executive roles at various companies.
Education includes undergraduate studies at The University of Nottingham.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/06/2026 | 280 160 ( 0,46 % ) | 28 M $ | 31/05/2026 | |
0,16 % | 04/06/2026 | 62 884 ( 0,16 % ) | 264 113 $ | 31/05/2026 |
| 21/05/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Michael Grey
| Sociétés | Poste | Début |
|---|---|---|
| MIRUM PHARMACEUTICALS, INC. | Fondateur | 07/05/2018 |
| SPRUCE BIOSCIENCES, INC. | Président | 01/04/2017 |
Biothera, Inc.
 Biothera, Inc. Miscellaneous Commercial ServicesCommercial Services Develops natural gluco polysaccharide that engages and directs natural innate immune systems | Directeur/Membre du Conseil | - |
Pappas Capital LLC
 Pappas Capital LLC Investment ManagersFinance Pappas Ventures invests in companies located in the across the globe and primarily in United States, Canada and Asia. The firm focuses on next-generation life science, agriculture, and technology. It participates in seed and early-stage transactions. | Private Equity Investor | 01/01/2010 |
Plexium, Inc.
 Plexium, Inc. BiotechnologyHealth Technology Develops drug discovery and targeted protein degradation therapeutics technology platform | Président | 01/08/2020 |
Sorriso Pharmaceuticals, Inc.
 Sorriso Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company advancing disease-modifying antibodies for the treatment of inflammatory disease | Président | 01/12/2017 |
Theolytics Ltd.
 Theolytics Ltd. BiotechnologyHealth Technology Engages in research and experimental development on biotechnology | Président | 30/11/2023 |
Anciens postes connus de Michael Grey
| Sociétés | Poste | Fin |
|---|---|---|
| ONKURE THERAPEUTICS, INC. | Directeur Général | 01/12/2017 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Directeur/Membre du Conseil | 06/10/2023 |
| ░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Michael Grey
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
73
Relations au 1er degré
33
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 33 |
|---|---|
Trega Biosciences, Inc.
 Trega Biosciences, Inc. BiotechnologyHealth Technology Provides identification and early stage development of novel and small moelcule drug therapies | Health Technology |
BioMarin Pharmaceutical, Inc.
 BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Epimmune, Inc.
 Epimmune, Inc. Pharmaceuticals: MajorHealth Technology Develops vaccines to treat and prevent infectious diseases and cancer | Health Technology |
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes treatments for infectious diseases | Health Technology |
Biothera, Inc.
Biothera, Inc. Miscellaneous Commercial ServicesCommercial Services Develops natural gluco polysaccharide that engages and directs natural innate immune systems | Commercial Services |
Lumena Pharmaceuticals, Inc.
 Lumena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oral therapeutics for rare liver diseases | Health Technology |
Horizon Therapeutics Ltd. (Ireland)
 Horizon Therapeutics Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
SGX Pharmaceuticals, Inc.
 SGX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops drugs and other pharmaceutical products | Health Technology |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Ventures invests in companies located in the across the globe and primarily in United States, Canada and Asia. The firm focuses on next-generation life science, agriculture, and technology. It participates in seed and early-stage transactions. | Finance |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cancer therapies | Health Technology |
Selventa, Inc.
 Selventa, Inc. Miscellaneous Commercial ServicesCommercial Services Develops new approaches for the understanding and treatment of diseases | Commercial Services |
The University of Nottingham
 The University of Nottingham Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IDM Pharma, Inc.
 IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops cancer treatment products | Health Technology |
San Diego Venture Group
 San Diego Venture Group Financial ConglomeratesFinance Provides funding for start up companies | Finance |
Ansan Pharmaceuticals, Inc.
 Ansan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Glaxo, Inc. | |
Glaxo Holdings Plc
 Glaxo Holdings Plc Financial ConglomeratesFinance Provides investment services | Finance |
Auspex Pharmaceuticals, Inc.
 Auspex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Biochem Therapeutic, Inc. | |
Amplyx Pharmaceuticals, Inc.
 Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes medicines | Health Technology |
Horizon Pharma, Inc.
 Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops medicines for the treatment of chronic inflammatory diseases | Health Technology |
Ziarco Pharma Ltd.
 Ziarco Pharma Ltd. BiotechnologyHealth Technology Provides therapeutics targeting inflammatory and allergic diseases | Health Technology |
Ziarco Group Ltd.
 Ziarco Group Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutics targeting skin inflammatory and allergic diseases | Health Technology |
Reneo Pharmaceuticals, Inc.
 Reneo Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases | Health Technology |
Balance Therapeutics, Inc.
 Balance Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for neurological disabilities | Health Technology |
Biothera Pharmaceuticals, Inc. (Delaware)
 Biothera Pharmaceuticals, Inc. (Delaware) Medical/Nursing ServicesHealth Services Develops cancer immunotherapy | Health Services |
Ansan, Inc.
 Ansan, Inc. MiscellaneousMiscellaneous Operates as a non-classified establishment | Miscellaneous |
Spruce Biosciences, Inc.
 Spruce Biosciences, Inc. BiotechnologyHealth Technology Operates as biopharmaceutical company which develops novel therapies for endocrine diseases | Health Technology |
Theolytics Ltd.
Theolytics Ltd. BiotechnologyHealth Technology Engages in research and experimental development on biotechnology | Health Technology |
Mirum Pharmaceuticals, Inc.
 Mirum Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage therapeutics company developing a novel approach for treating cholestasis liver diseases | Health Technology |
Plexium, Inc.
Plexium, Inc. BiotechnologyHealth Technology Develops drug discovery and targeted protein degradation therapeutics technology platform | Health Technology |
Curzion Pharmaceuticals, Inc.
 Curzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
Sorriso Pharmaceuticals, Inc.
Sorriso Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company advancing disease-modifying antibodies for the treatment of inflammatory disease | Health Technology |
